Award Data

DESCRIPTION (provided by applicant): Sudden cardiac death (SCD) results in approximately 450,000 deaths each year in the United States alone of older adults. Most fatal SCD events are caused by ventricular arrhythmias (ventricular tachycardia and ventricular fibrillation) in patients both with and without identified structural heart disease. Proposed is a personal ambulatory arrhythmia monitoring ...

DESCRIPTION (provided by applicant): Innovative Design Labs (IDL) proposes to develop a low-power, low-cost, high compliance system for monitoring gait parameters indicative of increasing fall-risk. Falls are the leading cause of morbidity and mortality in older people, and fall-related injuries represent a significant burden to the patients, their families, caregivers an the society as a whole. ...

DESCRIPTION (provided by applicant): Sepsis is a common and frequently fatal condition with a mortality rate that ranges from 20% to 50% for severely affected patients. It is the second leading cause of death in the U.S. among patients in non-coronary intensive care units and the 10th leading cause of death overall. It is a rapidly increasing health concern, especially for elderly, immune-compromi ...

DESCRIPTION (provided by applicant): The aim of this application is to develop a rapid, easy-to-use, and inexpensive test for urinary tract infection diagnosis using an ultrasensitive arrayed lateral flow nucleic acid biosensor (LFNAB) to identify uropathogens. UTI is the most common urological disease in the United States and is a major cause of patient morbidity and health care expenditure for a ...

DESCRIPTION (provided by applicant): Coccidioidomycosis, also known as Valley Fever, is a fungal disease caused by Coccidioides spp. that infects an estimated 150,000 people each year in the United States. Current diagnosis of coccidioidomycosis relieson detection of anti-coccidioidal antibodies in patient sera. However, the sensitivity of this serological assay is particularly low in the firs ...

DESCRIPTION (provided by applicant): This Small Business Innovation Research Phase I project is designed to develop new zwitterionic click methodology for orthopedic surfaces with enhanced durability. As Americans live longer and more actives lives, totaljoint replacement is becoming more common. Current orthopedic joints have average life spans of approximately 20 years. By that point wear on th ...

DESCRIPTION (provided by applicant): MicroRNAs (miRNAs) have emerged as a promising new class of therapeutics for cancer. miRNAs are small, non-coding RNAs that determine cell fate by post-transcriptionally regulating the expression of a broad but nevertheless specific set of genes. miRNAs can function as conventional oncogenes and tumor suppressors and, when misregulated by e.g. aberrant expressi ...

DESCRIPTION (provided by applicant): Mirna Therapeutics, a Texas-based company, is developing non-small cell lung cancer (NSCLC) therapies using tumor suppressor miRNAs. This approach, miRNA replacement therapy , is based on the concept that re-introduction of miRNAs depleted in cancer cells reactivates cellular pathways that drive a therapeutic response. Mirna is developing 5 miRNA candidates ...

DESCRIPTION (provided by applicant): Ensysce Biosciences Inc. is a biotechnology company located in Houston, TX, exploiting the pionering nanotechnology studies of the late 1996 Nobel Laureate, Dr. Richard Smalley of Rice University. The rights to Dr. Smalley's work on carbon nanotube technology in the area of therapeutics, as well as other critical carbon nanotube patents, have been in-licen ...

DESCRIPTION (provided by applicant): Multiple myeloma (MM) is the second most commonly diagnosed hematologic malignancy with an estimated 20,520 newly diagnosed cases and 10,610 deaths due to MM in the United States in 2011. MM is a disease of the elderlywith a median age at diagnosis of 70 years and 37% of patients older than 75 years. The number of geriatric MM patients is expected to increase ...